The $4.2 Billion Question: Why Most Dog Supplements Have Zero Clinical Evidence

Industry Analysis · 14 min read

✓ Our Investigations Desk — July 30, 2026

By David Okafor, Senior Industry Analyst  |  Published July 30, 2026  |  14 min read

Table of Contents

• The $4.2 Billion Question
• How We Investigated
• Top 10 Brands by Market Share vs. Clinical Evidence
• The Evidence Gap, By the Numbers
• Why Billions Get Spent With Almost No Canine RCTs
• What a Genuine Clinical Trial Actually Looks Like
• Our Findings
• Frequently Asked Questions
• References

The $4.2 Billion Question

Pet owners in the United States now spend more on supplements for their dogs than on many categories of human over-the-counter medicine. Depending on which market-research firm you consult, the global dog supplement market was valued somewhere between $2.7 billion and $3.7 billion in 2025, and is projected to climb to between $4.1 billion and $6.3 billion by the end of the decade. North America accounts for roughly^[3] 43–49% of that total. For shorthand, we will call it a $4.2 billion question — the midpoint of where the market is heading^[7].

The question is not whether the market is growing. It clearly is. The question is what, exactly, all that money is buying.

When a pharmaceutical company brings a new drug to market, it must first demonstrate — through phased, peer-reviewed, randomized controlled trials — that the drug is safe and effective for its intended use. That evidence is reviewed by a regulator before the product can be sold^[4]. The entire commercial value of the drug rests on published proof.

The dog supplement industry operates under none of those constraints. A supplement marketed for “gut health,” “immune support,” or “calming” is, in the eyes of U.S. regulators, a food product^[6] — not a drug. It does not have to prove efficacy before it reaches the shelf. It cannot legally claim to treat, cure, or prevent a disease, but it can imply a great deal through structure-and-function language, and it can decorate its packaging with words like clinically studied and science-backed — neither of which is a regulated term with a legal definition.

The core finding of this investigation: An industry that will be worth more than $4 billion within a few years is, for the most part, selling products that have never been the subject of a published, product-level randomized controlled trial in the species that actually takes them.

This is not, by itself, an accusation of wrongdoing. It is a description of an incentive structure. When a company can legally sell a supplement without ever demonstrating that the finished product works, the rational business decision is to invest in marketing that evokes science rather than in research that might disconfirm it. This article follows that logic — and quantifies the gap.

How We Investigated

We began by identifying the 10 dog supplement brands with the largest market share or highest reported revenue, cross-referencing published figures from multiple market-research firms (MarketsandMarkets, Grand View Research, Fortune Business Insights, IMARC Group) and, for direct-to-consumer companies, reported annual revenue. The resulting list spans multinational incumbents, veterinary-channel leaders, and venture- or private-equity-backed disruptors.

For each brand, we searched the peer-reviewed literature for product-level evidence and classified it on a four-tier hierarchy, from strongest to weakest:

1. Product-level canine RCT — a peer-reviewed, randomized, controlled trial conducted in dogs on the finished product or its specific branded strain.
2. Strain- or ingredient-level canine evidence — peer-reviewed studies in dogs, but on an ingredient or bacterial strain rather than the finished product as sold.
3. Non-canine or preclinical evidence — studies in humans, rodents, or in vitro, extrapolated to dogs.
4. No published product evidence we could locate — marketing claims we could not trace to a published study on the product.

Our companion investigation, The Clinical Trial Gap, examined 15 brands in greater depth. This article takes the wider, market-level view: where the money goes, and where the evidence does not.

Top 10 Brands by Market Share vs. Clinical Evidence

The table below summarizes our findings. Market position reflects published market-share or revenue ranges; evidence level reflects the strongest product-specific peer-reviewed evidence we could locate at the time of writing. “Editorial assessment” denotes our classification of the literature, not a laboratory finding.

Market-position ranges are drawn from published market-research reports and reported revenue; figures differ between firms and should be read as approximate. Evidence classifications are an editorial assessment of the published literature, not a laboratory result. “None we located” means we could not identify a qualifying published study after a reasonable search — it is not a categorical assertion that none exists.

The Evidence Gap, By the Numbers

Read the table from top to bottom and a pattern emerges. The companies with the deepest pockets and the longest histories — the multinationals and the veterinary-channel leaders — are generally the ones that have invested in published canine research. The direct-to-consumer disruptors, which collectively command hundreds of millions of dollars in revenue and dominate the bestseller lists, overwhelmingly have not.

Consider what the literature actually says about the single most heavily marketed “scientific” segment in the category: probiotics.

• A 2017 review in the Journal of the American Veterinary Medical Association concluded that “there currently is no definitive evidence that probiotics are effective for dogs with chronic diarrhea,” and that “a clear role for administration of probiotics to dogs and cats is not evident on the basis of the current literature” (Jugan et al., 2017).
• A 2019 randomized, double-blind, placebo-controlled trial in dogs with acute diarrhea found no statistically significant difference between a probiotic (measured at 70 billion CFU), metronidazole, and placebo for time to clinical resolution (Shmalberg et al., 2019).
• A 2021 longitudinal survey of healthy dogs given a commercial probiotic found that microbiome diversity “were not significantly altered after 2 weeks of probiotic administration, suggesting an absence of probiotic impact on microbial diversity” (Manson-Smith et al., 2021).

This is not fringe skepticism. It is the mainstream veterinary literature. And yet the probiotic segment alone is estimated to represent roughly a third of all pet dietary supplement sales.

Key Finding: The distance between what the marketing implies and what the peer-reviewed literature demonstrates is not a gap that a few studies could close. It is structural. The products generating the most revenue are, in many cases, the ones with the least product-specific evidence.

Why Billions Get Spent With Almost No Canine RCTs

To understand why a $4 billion market can function with so little clinical proof, you have to understand how the category is regulated — or, more precisely, how it is not.

Supplements are food, not drugs

In the United States, a product marketed to support a dog’s “gut health” or “immune function” is regulated as a food or an animal supplement, not as a drug. The practical consequence is enormous: there is no pre-market efficacy requirement. A brand does not have to run a single trial in dogs before selling. Our investigation of the regulatory framework, Regulatory Gap: Why the FDA Can’t Keep Up With Pet Supplement Claims, documents how thinly this space is policed relative to its size.

“Clinically studied” is not a regulated term

Phrases like clinically studied, science-backed, research-driven, and vet-formulated carry no legal definition. None requires a minimum standard of evidence. None is verified by a government agency before it appears on a label. In practice, “clinically studied” can mean anything from a genuine double-blind trial in dogs to a single in-vitro assay on one ingredient performed years ago in a different species.

Ingredient studies are cheap; product trials are expensive

It is far less expensive to cite an existing study on an ingredient — say, a published paper on a bacterial strain or a botanical — than to fund a new, product-level, randomized controlled trial in dogs. A properly designed canine RCT costs tens of thousands of dollars at minimum, takes months or years, and carries the genuine risk of producing a null result. From a pure return-on-investment standpoint, marketing that borrows the credibility of ingredient-level science is a rational substitute for research that tests the finished product.

The economics reward the evocation of science

Consumer purchasing behavior confirms the strategy works. Shoppers reward the aesthetics of rigor — white coats, molecular diagrams, PubMed citations on landing pages, CFU counts printed in large type. Few have the time or training to distinguish a product-level canine RCT from an ingredient study in mice. The market, as currently structured, pays brands to look scientific. It does not pay them to be scientific in the narrow, expensive, publishable sense.

What a Genuine Clinical Trial Actually Looks Like

Not all evidence is created equal, and consumers deserve a clear standard. In our assessment — an editorial assessment based on the published literature and standard principles of clinical research — a supplement earns the strongest form of credibility only when it can point to evidence meeting all of the following:

1. Randomized and controlled. Dogs are randomly assigned to a treatment group and a placebo or control group, so that differences in outcome can be attributed to the product rather than to chance.
2. Blinded. Ideally double-blind, so that neither the handlers nor the investigators know which animals received the active product — eliminating observer bias.
3. Conducted in the target species. In dogs, not extrapolated from humans or rodents. The canine microbiome and canine physiology are distinct; results do not always transfer.
4. On the finished product or its specific branded ingredient. Not merely on a generic ingredient that happens to appear in the formula.
5. Published in a peer-reviewed journal. With methods and data open to scrutiny — not a white paper on the brand’s own website.
6. Reporting a meaningful, statistically significant outcome. A measured effect with a reported p-value, not an anecdote or a before-and-after testimonial.

Measured against this standard, the picture sharpens. A handful of products clear the bar. They are concentrated, notably, in the emerging postbiotic category — preparations of inactivated microorganisms and their components, formally defined by the International Scientific Association of Probiotics and Prebiotics (ISAPP) in a 2021 consensus statement (Salminen et al., 2021). In 2024 and 2025 alone, multiple peer-reviewed, double-blind, placebo-controlled canine RCTs on specific postbiotic preparations were published, including trials demonstrating a 27% reduction in volatile sulfur compounds associated with canine halitosis (Sordillo et al., 2025) and a reduction in plaque biofilm accumulation (Florit-Ruiz et al., 2025), alongside a 2025 systematic review and meta-analysis of postbiotic administration in canine health (Bonel-Ayuso et al., 2025).

We want to be precise about what this does and does not show. There are not yet head-to-head trials proving postbiotics are superior to probiotics in dogs. What the record shows is that a tiny, fast-growing slice of the market has done the expensive, publishable, product-level work in dogs — while most of the $4 billion has not. For a consumer trying to spend on evidence rather than marketing, that distinction matters.

For the record, the product we kept encountering in that postbiotic cluster is — a direct-to-consumer all-in-one whose oral-health postbiotic (COHP) is the subject of the Sordillo 2025 canine trial cited in our references. We name it because it is the clearest example of the standard this article demands; our full assessment sits in the transparency spotlight below.

Our companion piece, The Oral Health Blind Spot, examines one specific area — the mouth — where the evidence gap is especially stark.

Related Investigations

• The Clinical Trial Gap: Which Brands Actually Publish Research
• The Oral Health Blind Spot: Why Dog Supplements Ignore the Mouth
• The Cold Chain Problem: Why Your Probiotic Might Be Dead Before You Buy It
• The Dosage Gap: Label Claims vs Actual Content in Dog Probiotics